The OncoCyte leadership team has a proven track record of successfully developing and commercializing healthcare products and creating programs that result in better patient care.
OncoCyte Team




William Annett William Annett joined OncoCyte as Chief Executive Officer in June 2015. Mr. Annett’s diagnostics industry experience includes his service as CEO of BioFX Laboratories, Inc., an in vitro diagnostic company successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company focused on diagnosis of the major diseases of pregnancy. Mr. Annett also founded a consumer products company, which became publicly traded on NASDAQ, during his six-year tenure as CEO, and then acquired. At Genentech, Mr. Annett led the Commercial Strategy group, managed large operational projects with several hundred team members, and directed the Project Finance function, which supported all pipeline products with more than 200 clinical trials. Most recently, Mr. Annett was a Managing Director at Accenture where he headed the West Coast Life Sciences practice with sales, marketing, and delivery responsibilities. His clients included most of the major biotech and pharmaceutical companies in the western United States. Mr. Annett is a member of the Board of Directors of the California Life Sciences Association. He holds an MBA from the Harvard Business School.




Lyssa Friedman Lyssa Friedman joined OncoCyte as a consultant in April 2014 and was named VP of Clinical and Regulatory Affairs in September 2015. Ms. Friedman started her career as a registered nurse specializing in oncology, and has led clinical research operations teams for more than 15 years. Ms. Friedman was a founding team member at Veracyte, where she executed a 49-site, 4000-subject clinical validation study that resulted in the launch of the Afirma® Gene Expression Classifier. She later oversaw clinical utility studies that contributed to positive coverage decision from the Centers for Medicare and Medicaid Services and major U.S private insurers. Ms. Friedman is an author of about a dozen peer-reviewed publications and is a frequent speaker on diagnostic development, clinical and regulatory affairs, and reimbursement. Ms. Friedman received her Masters in Public Administration from the University of San Francisco.




William Haack joined OncoCyte as Vice President of Market Access and Business Operations in June 2016. Mr. Haack has 20 years of life sciences experience, having leadership roles at Genentech, Genomic Health & Invitae. Mr. Haack had the great privilege of working on the teams at Genentech that launched Herceptin® and Rituxan® and was also involved in some of the early strategic work at Genentech in the area of molecular diagnostics. At Genomic Health, Mr. Haack lead both US and European Commercial Operations and Market Access teams during his 9 year tenure where he developed the department from infancy to over 120 people and nearly $300 million in annual global revenues. Mr. Haack also served as Adjunct Assistant Professor of Economics at Golden Gate University for 11 years where he taught micro and macro-economic theory. Mr. Haack received an MA in Economics at California State University, Hayward where he specialized in Econometrics.




Lyndal Hesterberg Lyndal Hesterberg Ph.D., joined OncoCyte as a consultant in 2015 and was named Vice President of Development in February of 2016. Dr. Hesterberg has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial design, product development and corporate strategy. Previously, he was the CTO at Crescendo Biosciences until 2012 where he was responsible for clinical trial, laboratory operations, manufacturing and quality systems and helped bring to market Vectra DA. Before that, he was the president and CEO of Barofold, Inc., where he led the Company from product conception through its clinical stage. He also recruited a senior leadership team that developed a pipeline of proprietary drug candidates. Dr. Hesterberg also has been a Director of Research, EVP of Scientific affairs and Manager of Diagnostic Product Development. He received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.




Kristine Mechem Kristine C. Mechem joined OncoCyte Corporation as Vice President of Marketing & Planning in August 2015. Dr. Mechem’s leadership and industry experience includes marketing, long range planning,  commercial opportunity assessments and analytic roles spanning from smaller early stage diagnostic companies such as Corra Life Sciences, to larger biopharma companies like Abbott and Genentech.

At Corra Life Sciences, a prenatal diagnostics company, she was a co-founder and in her business development and marketing role worked to secure co-development partners and to license IP from three prominent universities.  At Genentech, Dr. Mechem led the portfolio management and business planning process for a $400M product. Most recently, as a Director of Business Insights and Analytics at Abbott Diabetes Care, she led a team managing the business planning process and tracking key product performance.
Dr. Mechem holds a Ph.D. from the University of Chicago, and completed the Stanford Business School Executive Program in Strategy and Organization.




William Seltzer William K. Seltzer joined Oncocyte in September 2014 and in July of 2015 was appointed VP of Clinical Services. Dr. Seltzer is a board certified clinical molecular geneticist with 30 years commercial and academic experience in clinical diagnostic services and products development and commercialization, quality assurance and regulatory compliance. As an Associate Professor of Pediatrics at Colorado, he founded and directed the University’s DNA Diagnostic Laboratory. Dr. Seltzer has served as a member of the executive management team and/or as the Clinical Laboratory Director at a number of successful diagnostic companies including Athena Diagnostics, Veracyte and Counsyl. Over the course of his career, Dr. Seltzer has been responsible for the successful launch and oversight of clinical services for over 100 Laboratory Developed Tests (LDTs) in the fields of Neurology, Endocrinology, Nephrology, Molecular Cytology and Genetics. He has published more than 50 articles in peer-reviewed scientific journals and is co-inventor on patents for molecular diagnostics and methods. Dr. Seltzer received his Ph.D. in Pharmacology and Nutrition from the University of Southern California and completed his clinical fellowship in molecular genetics at the University of Colorado School of Medicine.




Russell Skibsted was appointed Chief Financial Officer of OncoCyte in November of 2015.  He brings over 25 years of experience in finance, acquisitions, partnering, marketing and operations for companies ranging in size from early stage to Fortune 50.   Mr. Skibsted’s Life Sciences financial experience includes roles in diagnostic (CFO at Proove Biosciences) and pharmaceutical companies (CFO at Aeolus Pharmaceuticals; Chief Business Officer at Spectrum Pharmaceuticals; and CFO at Hana Biosciences). At Spectrum, he led global strategy, mergers and acquisitions, licensing, fund raising and investor relations.   Mr. Skibsted led the IPO for Hana Biosciences and completed two rounds of financings. In addition to his Life Science industry experience, he served as Managing Director and CFO of RSL Ventures, where he provided financial consulting services to public and privately held Life Science companies. Mr. Skibsted has a degree in Economics from the Claremont McKenna College and an MBA from the Stanford Graduate School of Business.